OncoMatch/Clinical Trials/NCT06730347
A Study of Lorigerlimab in Participants With Advanced Solid Tumors
Is NCT06730347 recruiting? Yes, currently enrolling (May 2026). This Phase 2 trial studies Lorigerlimab for platinum-resistant ovarian cancer.
Treatment: Lorigerlimab — Study CP-MGD019-03 is an open-label study of lorigerlimab in participants with platinum-resistant ovarian cancer (PROC) or clear cell gynecologic cancer (CCGC). Approximately 60 participants will be enrolled. The study will assess the efficacy and safety of lorigerlimab in participants with PROC or CCGC. Participants will receive lorigerlimab by intravenous (IV) infusion on Day 1 of every 21-day treatment cycle. Treatment cycles will continue until progression of cancer, unacceptable side effects, withdrawal of consent by the participant, or the study ends. Participants will be monitored closely for side effects by physical exam and routine laboratory tests every cycle. Tumor status will be checked approximately every 9 weeks for the first year, then every 12 weeks for the duration of treatment. Participants will have a safety followup performed within 30 days after treatment discontinuation. Participants who discontinue study treatment for reasons other than progression of cancer, will continue CA-125 and tumor assessments every 12 weeks. Participants who discontinue study treatment for progression of cancer will enter the 6-month survival follow up portion of the study.
Check if I qualifyExtracted eligibility criteria
Cancer type
Ovarian Cancer
Cervical Cancer
Endometrial Cancer
Biomarker criteria
Allowed: BRCA1 mutation
Allowed: BRCA2 mutation
Disease stage
Excluded: Stage PRIMARY PLATINUM-REFRACTORY
Grade: high-grade
Persistent or recurrent disease with documented disease progression. Participants must have at least one lesion that meets the definition of measurable disease by RECIST v1.1.
Prior therapy
Must have received: PARP inhibitor — if BRCA-mutated and locally approved and available
Participants with a known breast cancer (BRCA) mutation (germline or somatic) must have received a Poly ADP-ribose polymerase (PARP) inhibitor, if locally approved and available, and experienced disease progression or intolerance on the PARP inhibitor.
Cannot have received: checkpoint inhibitor (anti-PD-1, anti-PD-L1, anti-PD-L2, anti-CTLA-4)
Exception: Prior use of immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) is allowed for clear cell endometrial and clear cell cervical cancer.
Prior treatment with a checkpoint inhibitor (e.g., anti-PD-1/PD-L1, anti-PD-L2, anti-CTLA-4). Prior use of immune checkpoint inhibitors (e.g., anti-PD-1, anti-PD-L1, anti-CTLA-4) is allowed for clear cell endometrial and clear cell cervical cancer.
Cannot have received: stem cell transplant
Prior stem cell, tissue, or solid organ transplant.
Cannot have received: tissue or solid organ transplant
Prior stem cell, tissue, or solid organ transplant.
Structured fields extracted by AI. May contain errors — verify against the official protocol.
US trial sites
- UCLA · Los Angeles, California
- Ochsner MD Anderson Cancer Center · New Orleans, Louisiana
- START Midwest · Grand Rapids, Michigan
- West Penn Allegheny Health · Pittsburgh, Pennsylvania
- Mays Clinic · Houston, Texas
Showing up to 5 US sites. See all sites on ClinicalTrials.gov →
Could you qualify for this trial?
Enter your biomarker results to see how this trial's eligibility criteria match your specific cancer profile.
Check if I qualify